## **Core Concept**
Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) characterized by the accumulation of abnormal promyelocytes in the bone marrow and peripheral blood. It is associated with a specific chromosomal translocation that leads to the formation of an oncogenic fusion protein. This translocation involves the retinoic acid receptor-alpha (RARα) gene.

## **Why the Correct Answer is Right**
The correct answer, , refers to the t(15;17) chromosomal translocation. This translocation results in the fusion of the promyelocytic leukemia (PML) gene with the retinoic acid receptor-alpha (RARα) gene, creating the PML-RARα fusion protein. This abnormal protein disrupts the normal process of myeloid cell differentiation and leads to the development of APL. The PML-RARα fusion protein acts as a dominant repressor of retinoic acid receptor function, preventing normal myeloid cell maturation.

## **Why Each Wrong Option is Incorrect**
- **Option A:** . This option is incorrect because while other translocations can be associated with AML, they are not characteristic of APL.
- **Option B:** . This is incorrect as it refers to a different condition; t(9;22) is characteristic of chronic myeloid leukemia (CML) and some cases of AML, leading to the BCR-ABL fusion gene.
- **Option C:** . This option is incorrect because, although t(8;21) is a common translocation in AML (particularly in the M2 subtype), it is not specific to APL.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that the t(15;17) translocation and the resultant PML-RARα fusion protein are specifically targeted by all-trans retinoic acid (ATRA) and arsenic trioxide, which are treatments for APL. This targeted therapy can induce differentiation of the leukemic promyelocytes into mature cells, thereby improving outcomes.

## **Correct Answer:** . t(15;17)